treatment news

PrEP use in US exceeds 100,000 in Gilead pharmacy survey

At the recent IAS meeting McCallister’s team presented the latest survey results, adding detailed data on PrEP prescriptions to September 2016, as well as an estimate through the first quarter of 2017. The survey looked at de-identified patient-level electronic...

read more

Boosted darunavir plus lamivudine matches three-drug regimen

A combination of darunavir/ritonavir and lamivudine was just as effective as the same combination plus tenofovir, according to 24-week results of the ANDES study presented last month by Professor Pedro Cahn at the 9th IAS Conference on HIV Science in Paris (IAS 2017)....

read more

Can we achieve a complete HIV cure in more patients?

What all the different approaches discussed in the previous report have in common is to put HIV infection into persistent remission, but they do not completely remove HIV from the body. But in what is still the one case of a person cured of HIV, that is what was...

read more

What marks out HIV controllers from others?

What if we are asking the wrong, question, though? What if trying to destroy or at least expose and inactivate every cell containing HIV is not the way forward and instead the answer is to teach the body to simply either ignore HIV, or develop an immune response that...

read more